

# Madelyn Burkart

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4839726/publications.pdf>

Version: 2024-02-01

27  
papers

415  
citations

840119

11  
h-index

794141

19  
g-index

27  
all docs

27  
docs citations

27  
times ranked

569  
citing authors

#	ARTICLE	IF	CITATIONS
1	Structural racism is a mediator of disparities in acute myeloid leukemia outcomes. <i>Blood</i> , 2022, 139, 2212-2226.	0.6	34
2	Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor Tâ€cell therapy for Bâ€cell nonâ€Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2022, 197, 71-75.	1.2	6
3	Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors. <i>Journal of Personalized Medicine</i> , 2022, 12, 376.	1.1	9
4	Outcomes of <sc><i>TP53</i></sc>â€mutated <sc>AML</sc> with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	24
5	Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse. <i>Case Reports in Hematology</i> , 2022, 2022, 1-4.	0.3	1
6	Racial disparities in patients with <i>TP53</i> mutated acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19007-e19007.	0.8	0
7	Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome. <i>Leukemia</i> , 2021, 35, 2097-2101.	3.3	9
8	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021, 137, 374-386.	0.6	59
9	Sequencing of novel agents in relapsed/refractory Bâ€cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 1039-1048.	2.0	16
10	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021, 106, 1932-1942.	1.7	21
11	Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. <i>Bone Marrow Transplantation</i> , 2021, 56, 1998-2004.	1.3	11
12	Cachexia is an independent factor for negative clinical and functional outcomes in lymphoma patients receiving CART therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19504-e19504.	0.8	0
13	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310.	1.1	3
14	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	2.5	24
15	Impact of initial chemotherapy regimen on outcomes for patients with doubleâ€expressor lymphoma: A multiâ€center analysis. <i>Hematological Oncology</i> , 2021, 39, 473-482.	0.8	5
16	Multiâ€center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021, 96, 1374-1384.	2.0	11
17	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	2.5	21
18	Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Oncologist</i> , 2020, 25, 878-885.	1.9	28

#	ARTICLE	IF	CITATIONS
19	Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. <i>Blood Advances</i> , 2020, 4, 2308-2316.	2.5	29
20	Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 556-560.e2.	0.2	12
21	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262.	2.5	29
22	Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. <i>Oncologist</i> , 2020, 25, e993-e997.	1.9	7
23	Older patients with mantle cell lymphoma (MCL): Practice patterns and predictors of survival in the rituximab era.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20064-e20064.	0.8	0
24	Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. <i>Blood</i> , 2020, 136, 49-50.	0.6	1
25	Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 45-53.	1.2	25
26	Future health of AYA survivors. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27516.	0.8	21
27	Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. <i>Blood</i> , 2019, 134, 402-402.	0.6	9